开发新型抗微生物药物,使用工程内素LysECD7-SMAP来对抗格拉姆阴性细菌感染
Daria V Vasina1, Nataliia P Antonova2, Vladimir A Gushchin2,3
1N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia. d.v.vasina@gmail.com.
Journal of biomedical science
|July 23, 2024
概括
工程内素显示希望作为新型治疗对抗多药耐药的阴性细菌. 临床前研究证实了LysECD7-SMAP在治疗严重感染的系统和局部应用中的有效性.
科学领域:
- 微生物学和生物技术
- 药物发现和开发 药物发现和开发
- 结构生物学 结构生物学
背景情况:
- 有限的非传统抗菌剂向关键的格拉姆阴性病原体,如耐卡巴尼姆*Pseudomonas aeruginosa*和*Acinetobacter baumannii*.
- 内素提供了一种新的作用模式,符合世卫组织的创新标准,并显示出对没有已知的交叉耐药性格拉姆阴性细菌的潜在作用.
研究的目的:
- 调查工程内素LysECD7-SMAP及其配方剂型的应用策略和疗效.
- 评估LysECD7-SMAP作为治疗多药耐药性格拉姆阴性细菌感染的治疗剂的潜力.
主要方法:
- LysECD7-SMAP 的基因工程,重组蛋白质的生产和晶体结构分析.
- 分子动力学模拟和对各种病原体的抗菌性质的评估.
- 溶解粉末注射剂和基乙纤维素凝的配方,用于局部使用.
- 临床前的疗效研究中,小鼠和老鼠模型的败血症,肺炎,伤口感染和伤口烧伤.
主要成果:
- LysECD7-SMAP对广泛的格兰氏阴性病原体表现出活性,包括多种耐药菌株,如 *Klebsiella pneumoniae*, *A. baumannii* 和 *P. aeruginosa*.
- 酶的催化域具有保存的内酶结构,具有C端抗微生物.
- 在体内研究证实了开发的剂型在动物模型中治疗细菌感染的有效性.
结论:
- 莱斯ECD7-SMAP治疗药物显示出系统或局部治疗格兰氏阴性细菌感染的显著潜力.
- 在临床试验中,基于LysECD7-SMAP的抗微生物药物的进一步推进是有必要的.
- 这项研究强调了工程内素作为一种新型抗菌剂的可行性.
相关概念视频
Antimicrobial Proteins
965
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
965
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Lytic Cycle of Bacteriophages
70.6K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.6K
Defense Against Bacterial Pathogens
1.4K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K
Antibiotic Selection
52.9K
Overview
52.9K


